Population
18 GBS- or MFS-related Campylobacter jejuni strains and 17 control strains from The Netherlands and Belgium
Comparison
Molecular characterization including serotyping… vs 17 control strains
Design
Preclinical
Authors
Loading...
Absence of distinguishing markers advises against relying on current typing for GBS risk stratification; leaves open identification of novel virulence determinants.
There is substantial molecular heterogeneity among C. jejuni strains associated with GBS and MFS, indicating that specific molecular markers for these pathogenic strains remain unidentified by standard typing methods.
Endtz et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: